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Abstract
Bisphosphonates are used in the treatment of hypercalcemia of malignancy, skeletal complications 
associated with metastastic bone disease, Paget’s disease, and osteoporosis. Osteonecrosis of the 
jaw (ONJ) is a recently described clinical condition that has been associated with the use of 
nitrogen-containing bisphosphonates. Reports describing this entity first appeared in the literature 
in 2003. While there have been significant numbers of case reports and a limited number of 
retrospective and prospective studies examining risk factors associated with ONJ, the 
pathophysiology of this condition remains elusive. In this review, we explore proposed 
mechanisms underlying ONJ development and identify potential areas for future investigation.
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Introduction
Bisphosphonates (BPs) are a widely used class of drugs indicated for the prevention and 
treatment of postmenopausal and steroid-induced osteoporosis; Paget’s disease of the bone; 
hypercalcemia of malignancy; multiple myeloma; and bone metastases associated with 
breast, prostate, lung, and other soft tissue tumors.1–4 In late 2003, a letter to the Journal of 
Oral and Maxillofacial Surgery described 36 patients who developed avascular necrosis of 
the jaw after receiving intravenous BPs.5 Twenty-four patients were on pamidronate (90 mg 
monthly) and 12 patients were receiving zoledronate (4 mg monthly). Patients were 
receiving BPs for multiple myeloma,18 metastatic breast cancer,17 and osteoporosis.1 All 
patients presented with painful, necrotic bone in the mandible (80%), maxilla (14%), or both 
(6%). In 78% of cases, the necrosis was associated with a prior history of tooth extraction. 
The remainder of cases appeared to arise spontaneously.5 Following this report, Migliorati et 
al.6 documented an additional five cases of suspected BP-associated osteonecrosis of the 
mandible. Three cases developed spontaneously and two cases occurred in patients with 
previous tooth extraction. No information regarding the patients’ diagnoses or duration of 
BP therapy was presented. Interestingly, prior to the initial report, Wang et al.7 reported on 
three females who developed jaw necrosis while receiving chemotherapy for metastatic 
breast cancer. Two of the patients had a previous history of dental manipulation. 
Histological evaluation of all three cases revealed necrotic bone without evidence of 
metastases. At the time of the initial report, the authors postulated that the osteonecrosis was 
a consequence of the cancer chemotherapy. In a follow-up communication, however, the 
authors noted that the patients had been treated with BPs.8
In late 2004, Ruggiero et al.9 reported on 63 cases of BP-associated osteonecrosis accrued 
over a 26-month period from two medical centers. Twenty-eight of the 63 patients had 
multiple myeloma, 20 patients had breast cancer, 3 patients had lung cancer, and 1 patient 
each had plasmacytoma and leukemia. All patients within the oncologic group were 
receiving chemotherapy and/or corticosteroids. Seven patients were diagnosed with 
osteoporosis and had no prior history of treatment with chemotherapeutic agents or 
corticosteroids. Thirty-nine patients presented with osteonecrosis of the mandible and 23 
had maxillary involvement; one patient had necrotic lesions in both jaws. Fifty-four of 63 
patients reported a recent extraction at the necrotic site while the remaining nine patients had 
apparent spontaneous bone exposure. Bacterial culture results were reported as normal oral 
flora in all cases. The reported length of BP therapy in this series ranged from 6 to 48 
months although the treatment time for each individual patient was not specified. Treatment 
of the necrotic jaw lesions ranged from conservative management to resection with the 
majority of patients undergoing sequestrectomy. In a follow-up report to their 2003 letter, 
Marx et al. documented an additional 119 patients with osteonecrosis of the jaw (ONJ). 
Similar to other case series, the majority of patients were undergoing treatment for multiple 
myeloma (52.1%) and metastatic breast cancer (42%). The mandible was the most common 
site of bone exposure (68.1%) and ongoing periodontal disease was present in a significant 
number of patients (84%).10
ONJ is a clinical term that has been defined by a number of professional associations.11–17 
Although there are slight differences in the various definitions, all involve a breach in 
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mucosa leading to exposed bone that fails to heal in 6–8 weeks; furthermore, there should be 
no history of head and neck radiation in the affected patients. Over the past several years, 
there have been numerous case reports and series, a limited number of retrospective studies, 
and a handful of small prospective studies that strongly suggest a link between BP therapy 
and ONJ; however, a definitive cause-and-effect relationship between the two has yet to be 
established. Many questions regarding the incidence, pathoetiology, and natural history of 
this condition still need to be answered. In this paper, we review the potential mechanisms 
of ONJ development that have been proposed thus far. We will focus on the effect of BPs on 
epithelial cells, bone cells, and angiogenesis. Moreover, the potential role of immune 
dysfunction and other contributing factors in the pathogenesis of ONJ will be discussed. 
Finally, an instrument to risk stratify individual patients for the development of ONJ will be 
introduced.
Why the jaw?
Without a doubt, there are several features that make the oral cavity a unique environment. 
The anatomy is such that the alveolar bone in both the mandible and maxilla is covered by a 
thin layer of periosteum and epithelium with an attenuated layer of connective tissue. The 
oral structures are subjected to a wide variety of stresses, which may be physiologic (e.g., 
mastication), iatrogenic (e.g., dental procedures), or inflammatory (e.g., periodontal disease, 
caries) in nature. This combination of constant stress not only predisposes the thin mucosa to 
trauma, leading to exposure of bone, but likely demands an increase in metabolic 
compensation including bone remodeling. Furthermore, the oral cavity and teeth are 
colonized by a complex microbial flora, many of which are pathogenic organisms. The 
intimate relationship of teeth to the jaws allows a portal of entry for microbes and other 
inflammatory products to the underlying bone, a situation that is not found in any other part 
of the body.
The role of specific microbes in the development of ONJ is not completely resolved. Of 
interest, several authors have documented the presence of Actinomyces in their cases of 
ONJ. Lugassy et al.18 described two patients with multiple myeloma on long-term BP 
therapy. Histological examination of both specimens revealed necrotic bone surrounded by 
abundant microbial colonies with features of Actinomyces. Melo and Obeid19 reported a 
case of maxillary osteonecrosis with histological evidence of Actinomyces in patients with 
metastatic breast cancer on zoledronate. Hansen et al.20 examined histopathological 
specimens from 45 patients with Actinomycosis and confirmed the presence of Actinomyces 
colonies in 43/45 (93.5%) patients with either ONJ (58.7%) or infected osteomyelitis 
(35.6%). Three patients (6.7%) were not receiving chemotherapy of any kind. Histochemical 
analysis, standard gram stains, scanning electron microscopy, as well as polymerase chain 
reaction (PCR) testing was used to demonstrate Actinomyces species.
A recent retrospective study by Kos et al.21 examined 29 patients with ONJ. The authors 
performed a chart review and evaluated patients with delayed wound healing, bone 
sequestration, abscess formation, and recurrent wound dehiscence from January 2003 to 
December 2006. Cases of osteoradionecrosis (ORN) and open fractures were excluded. 
Patients were divided into two groups: those treated with BPs and those who had no 
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documented history of BP use. The BP-treated group included 18 patients–12 with multiple 
myeloma, 3 with breast cancer, 2 with prostate carcinoma, and 1 with osteoporosis. The 
patients who had not been treated with BPs included two patients with breast cancer, two 
patients with lung cancer, and seven without cancer. Statistical analysis failed to show 
differences between the two groups in the recurrence rate of wound dehiscence. There were 
no effects from chemotherapy or steroid therapy on wound healing and there were no 
associations between wound dehiscence and the duration of BP treatment or the type of BP 
therapy used. Of interest was the observation of a statistically significant increase in 
Actinomyces colonization of exposed bone in the BP treated group (11/18; 61%) when 
compared to the nontreated group (2/11; 18%, P = 0.021).
Actinomyces are a normal inhabitant of the oral environment, and can be a component of 
dental plaque and calculus, gingival sulci, and periodontal pockets.22 The pathogenic 
potential of Actinomyces is well-recognized, and Actinomyces have been documented in 
various sites within the cervicofacial region including the jawbones (so-called 
“actinomycotic osteomyelitis”). The presence of Actinomyces species in significant numbers 
of ONJ histological specimens has led Naik and Russo23 to suggest a critical role of this 
organism in the development of ONJ. It remains unclear, however, whether actinomycotic 
colonization occurs as a primary event or as a secondary phenomenon due to its prevalence 
in the oral cavity. Furthermore, histological identification of Actinomyces can be challenging 
at times, as many bacterial organisms can exhibit actinomycotic-like morphology. 
Therefore, only a strong presumptive diagnosis of actinomycosis can be rendered in the 
absence of culture confirmation.24
Do BPs cause an oversuppression of bone turnover?
Several authors have proposed that BPs cause excessive reduction of bone turnover resulting 
in an increased risk of bone necrosis when the demand for osseous repair is present.25–27 
This theory, however, fails to explain why exposed necrotic lesions are rarely seen in bones 
other than the jaws. In addition, a number of studies have failed to demonstrate that BPs 
reduce bone turnover to the extent that they cause adynamic bone. A study by Chapurlat et 
al.25 examined transiliac bone biopsies from postmenopausal women and found no 
significant difference from controls in the number of microcracks after at least three years’ 
treatment with a BP (3 subjects on intravenous pamidronate, 37 on oral alendronate, and 10 
on oral risedronate), despite a marked reduction in bone turnover. Stepan et al.26 compared 
transiliac bone biopsies obtained from 38 postmenopausal women treated with daily or 
weekly alendronate for a mean duration greater than 5 years to biopsies from 28 treatment-
naive women with postmenopausal osteoporosis. No differences in crack surface density or 
crack density between the two groups were found. There was, however, a correlation 
between low femoral neck density and increased microcrack accumulation following 
alendronate treatment after adjustment for potential confounders.26 In addition, several long-
term clinical trials that evaluated the ability of BP treatment to reduce fracture risk in 
postmenopausal osteoporosis have showed that after the initiation of BP therapy, bone 
turnover rapidly returned to, and remained within the premenopausal range, with no 
additional fracture risk associated with long-term treatment.27 Furthermore, there have been 
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no documented cases of ONJ due to an excessive reduction in bone turnover secondary to 
BP therapy.
The effect of BPs on epithelial cells and wound healing
Numerous studies have explored the effect of BPs on a variety of epithelial cells, including 
gastrointestinal cells, cervical epithelial cells, renal cells, prostate epithelial cells, and oral 
mucosal cells. The development of gastric erosions and ulcers is a well-documented side 
effect associated with oral administration of nitrogen-containing BPs. Several investigators 
have demonstrated the adverse effects of exposing gastrointestinal cells to BPs. Twiss et 
al.28 confirmed the cytotoxic effects of pamidronate on Caco-2 intestinal cells by 
demonstrating increased cell permeability after BP exposure in vitro. In a subsequent 
investigation, this same group29 incubated Caco-2 epithelial cell cultures with various 
concentrations of two nitrogen-containing BPs, pamidronate and alendronate. They observed 
that in the presence of calcium, both BPs were toxic to the cells. However, only pamidronate 
exhibited toxicity when calcium was absent from the media. Furthermore, they demonstrated 
that pamidronate forms insoluble complexes with calcium that deposit on the cell surface, 
exposing them to locally increased and cytotoxic concentrations of the drug. Neither of the 
BPs induced apoptosis of the cells. Wallace et al.30 used an ex vivo gastric chamber model 
to show concentration-dependent epithelial injury and loss of integrity after exposure to 
pamidronate and alendronate. Exposure to the drug caused necrosis of the gastric 
epithelium, and the mechanism of damage was independent of microvascular injury, 
possibly due to disruption of surface-active phospholipids within the mucosal layer. Suri et 
al.31 exposed Caco-2 cells to various BPs in vitro and evaluated apoptosis by nuclear 
morphometry and TUNEL assays. In contrast to the results of Twiss et al.,29 they found a 
dose-dependent increase in apoptotic cells, reduction in cell viability, and inhibition of cell 
proliferation with pamidronate, among other BPs. Apoptosis and loss of viability was 
prevented when BP-induced inhibition of farnyldiphosphate (FPP) synthase—an enzyme in 
the mevalonate pathway—was bypassed by addition of geranylgeraniol, a downstream 
protein. They postulated that the toxic effects that BPs had on intestinal cells were likely 
related to disruption of the mevalonate pathway, which thereby reduces production of 
cholesterol precursors and interferes with cell membrane biosynthesis.
Giraudo et al.32 found that cervical epithelial cells treated with zoledronate in vitro exhibited 
increased apoptosis. Similarly, Perazella et al.33 demonstrated an increase in apoptosis in 
renal cells treated with pamidronate. Finally, Montague et al.34 examined prostate epithelial 
cells treated with zoledronate and confirmed a reduction in cell proliferation rate.
We have investigated the effects of BPs on oral epithelial cells. Mouse oral keratinocytes 
were isolated as previously described by Landesberg et al.35 and treated with pamidronate at 
various doses. Cell proliferation and apoptosis assays (Caspase-3, TUNEL assay, DAPI 
staining) were performed. In addition, the effect of pamidronate on in vitro wound healing 
was examined. Oral keratinocyte proliferation was assayed at 24, 48, 72, and 168 h with 0, 
0.03, 0.1, and 0.3 mM pamidronate concentrations. The results, shown in Figure 1, 
demonstrate that pamidronate inhibits cellular proliferation at a concentration of 0.1 mM. 
When the cells were exposed to concentrations below 0.1 mM there was no significant 
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difference in cell growth; however, exposure to pamidronate at higher doses caused the cells 
to be released from the plate within 2 h (data not shown). The relative number of viable cells 
in the 0.1 mM BP group did remain constant over the course of 7 days.
The ability of pamidronate to induce apoptosis in oral keratinocytes was evaluated using 
three different methods: the upregulation of caspase-3, fragmentation of DNA by a TUNEL 
assay, and analysis of apoptotic nuclei visualized with DAPI staining. The results of the 
caspase-3 assays are shown in Figure 2. Enzyme levels in the wells treated with 0.03 and 0.1 
mM pamidronate showed a significant increase at 24 and 48 h when compared to the 6-h 
sample; however, caspase-3 levels were not significantly different from the control levels. 
Cells that were treated with 0.3 mM of pamidronate showed a decrease in caspase-3 levels at 
24 and 48 h coincident with the release of cells from the plate. The cells treated with 
staurosporine and cycloheximide, agents known to cause significant apoptosis, showed an 
upregulation of caspase-3 at all time points that was between four- and sixfold higher levels 
than that seen in any of the cells that received pamidronate.
Analysis of the percentage of apoptotic cells was performed by counting the number of 
TUNEL positive cells in five high-power fields of approximately 100 cells. Approximately 
2% of cells treated with 0.03, 0.1, and 0.3 mM pamidronate for 24 h were TUNEL positive, 
similar to untreated control cells. In contrast, the positive control, cells treated with 200 nM 
staurosporine and 10 um cycloheximide, had nearly 100% TUNEL-positive cells. At 48 h 
the findings were similar to that seen at 24 h; however, many of the cells in the 0.3 mM 
pamidronate samples had floated off of the slide. The 6-h time point showed minimal effects 
in the pamidronate-treated samples, with only about 50% of TUNEL-positive cells seen in 
the positive control (data not shown). These results are consistent with the caspase-3 assay 
results (discussed earlier) as well as quantitation of DAPI stained pyknotic nuclei in cells 
treated with 0, 0.03, 0.1, and 0.3 mM pamidronate, respectively (data not shown).
The in vitro model of wound healing was used to examine the effects of pamidronate 
treatment on the ability of oral keratinocytes to migrate and proliferate in a monolayer 
culture. The results are shown in Figure 3. In the preincubated samples, the control and 
0.003, 0.01, and 0.06 mM pamidronate groups, cellular migration was appreciated beginning 
at 6 h and the wound was completely closed at 72 hours. The 0.1 mM preincubated group 
had a significantly delayed wound closure at all time points but did close when incubated for 
5 days (data not shown). The plates that had BP added immediately after wounding (no 
preincubation) had a response that was identical to the control samples.
Primary human oral epithelial cell cultures were established from discarded gingival tissue. 
The tissue was placed in dispase solution (Roche) and incubated at 4°C overnight. 
Epithelium was removed from the submucosal layer, minced, dissociated with TrypLE 
Express reagent (Invitrogen), pelleted, washed, and resuspended in low calcium DMEM 
with 15% chelated fetal bovine serum (FBS). The cells were cultured until colonies formed. 
Inhibition of proliferation by pamidronate was similar to that seen in mouse keratinocytes 
(Fig. 4).
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Given these data, the question that invariably arises is, How do oral epithelial cells get 
exposed to the BPs in vivo? It is well known that following administration of BPs, both 
orally and intravenously, a significant amount of drug is sequestered in bone. In cancer 
patients with bone metastases and normal kidney function, this amount has been estimated 
to be around 65% of an intravenous dose.36 Data on actual concentrations of pamidronate as 
well as other BPs deposited in human bone are limited. Extrapolating pharmacokinetic data 
in humans on whole body retention after 4 years of treatment with 90 mg of intravenous 
pamidronate, an estimated bone concentration of around 475 ng/mg of bone tissue (which 
equals 1575 nmol/g) would be expected. Of note, such calculations, which also have been 
made by Reid for zoledronate,37 result in an estimated pamidronate bone concentration that 
is similar to those extrapolated from data on actual bone concentrations in animals such as 
dogs and mice assessed using 14C-labeled pamidronate. When extrapolated from the 
published canine data,38 90 mg of pamidronate every 4 weeks over a 4-year period would 
lead to a bone concentration in humans of 240 ng/mg, while data extrapolated from mice 
with a similar regimen would lead to a bone concentration of 155 ng/mg.39 It therefore 
seems reasonable to assume that the average bone concentration in humans after 4 years of 
90 mg of pamidronate every 4 weeks ranges somewhere between 100 and 1000 ng/mg (or 
0.33–3.32 nM assuming 1g bone = 1 mL). Little is known, however, about the concentration 
of BP in various parts of the skeleton, as well as concentrations in bone sites with increased 
bone turnover such as a Pagetic lesion or alveolar bone following a surgical procedure. Data 
gained by using 99mTc-labeled BPs have shown that there is preferential uptake of BP in 
these sites, but the exact concentrations have yet to be determined. Data collected in rodents 
clearly show a noneven distribution of BPs throughout the skeleton, and also throughout 
single bones, especially in case of metastatic bone disease.40–42 At the present time, the 
actual amount of BP that is deposited within the human maxillofacial bones following 
intravenous administration is not known. Furthermore, although it has been speculated that 
gingival crevicular concentrations of BP are similar to bone concentrations,37 there are no 
data to support this to our knowledge, and there are no data on BP concentrations in gingival 
crevicular fluid or saliva. Various factors may promote BP release from the bone reservoir, 
including but not limited to trauma from dentoalveolar manipulation and inflammation from 
active periodontal disease. It is reasonable to postulate, however, that such factors may 
stimulate the release of BPs from the underlying alveolar bone, resulting in local increases in 
BP concentrations within the oral environment. Should the BP concentrations achieve toxic 
levels, the oral epithelial changes described may ensue.
While the emphasis thus far in ONJ research has been focused on bone necrosis being the 
primary event—an “inside-out” theory—it is intriguing to speculate that the adverse effects 
of BPs on oral epithelium may play a critical role in the initiation of ONJ—an “outside-in” 
hypothesis. Furthermore, this theory is consistent with the currently accepted definitions of 
ONJ, all of which include a breach in mucosa as a necessary event in developing this 
condition.
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Are osteoblasts from the craniofacial skeleton different from other 
osteoblasts?
Inherent differences between bone forming cells of the jaw and other parts of the skeleton 
may potentially influence the development of ONJ. During embryonic development, the 
skeleton arises from three distinct lineages: the craniofacial skeleton is formed by cranial 
neural crest cells, the axial skeleton is derived from paraxial mesoderm, and the 
appendicular skeleton is the product of lateral plate mesodermal cells.43 Additionally, in 
regions of the craniofacial skeleton and the clavicle, osteoblastic differentiation forms 
intramembranous bones directly, whereas in the remaining skeleton, bones are formed via 
endochondral ossification, which includes formation of cartilage models and their 
replacement by bone tissue.
Most of our knowledge about the skeleton is derived from experimental animal studies and 
investigations of human bone disorders,43,44 and there has been relatively little work 
comparing the nature of the cells in various parts of the skeleton. Declercq et al.45 isolated 
and cultured rat cells from fetal calvaria, fetal long bones, and adult long bone. They showed 
significant differences in cellular proliferation and in vitro mineralization between fetal and 
adult bone, as well as between different cell isolation procedures and passage number.46 A 
study of human cells derived from long bones of young men indicated that the sequence of 
in vitro osteogenesis is similar to that of rat calvarial cultures,47 and a study of human 
calvarial samples indicated age-related changes in bone formation, osteoblastic cell 
proliferation and differentiation.48 Interestingly, different expression patterns of bone 
morphogenic proteins were reported for human intramembraneous and endochondral bone 
and these were maintained in ex vivo osteoblastic cell cultures.49
Our preliminary results indicate differences in cell populations obtained from human 
alveolar and long bone samples (Fig. 5). Primary human osteoblasts were isolated from 
discarded alveolar and long bone surgical procedures. All protocols were approved by the 
IRB. The tissue was minced, washed, and cultured in DMEM/F12 medium supplemented 
with 20% FBS, gentamicin, and fungizone. Proliferation of the first and third passage cells 
was tested and compared between the two tissue sources. Alveolar bone cells exhibited 
sustained proliferation from days 1–7, reaching between 2–3 doublings, while long bone 
cells exhibited minimal proliferation, reaching up to one population doubling during 7 days 
of culture. Cell growth stopped in most long bone samples by passage two. Additionally, the 
morphology of the cultured cells was different between the two cell sources.
In a study by Stephanik et al.,50 pamidronate treatment of primary human mandibular and 
iliac crest bone marrow stem cells from the same donors showed differences in cell survival, 
osteogenesis, and osteoclast recruitment, suggesting possible dysregulation of mandible 
bone homeostasis after BPs exposure. Further studies detailing unique cellular 
characteristics of alveolar bone as well as the potential differences of alveolar bone cells in 
response to BPs when compared to long bone are clearly indicated in defining the potential 
pathophysiological mechanisms of ONJ.
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Are osteoclasts from the craniofacial skeleton different from other 
osteoclasts?
Evidence exists that osteoclasts derived from site-specific locations may show significant 
differences in their functional activity. Several studies by Everts et al.51,52 have evaluated 
the proteolytic enzyme profiles of osteoclasts derived from calvarial bone (intramembranous 
bone) and long bone osteoclasts (endochondral bone). These authors performed 
morphometric analysis using specific inhibitors for cysteine proteinases (CP, cathepsins) and 
for Matrix MetalloProteinases (MMPs) in a bone explants cultures. Isolated calvarial and 
long bone osteoclasts were examined for tartrate resistant acid phosphatase (TRAP) activity, 
immunolocalization of αvβ3 integrin receptors, and the ability to form resorption pits on 
bone slices in the presence of the different CP and MMP inhibitors. While the TRAP and 
integrin receptors were comparable in the different osteoclasts, the morphometric results 
demonstrated that while osteoclastic activity in both the long bones and calvaria are 
dependent on CPs, MMPs are critical only in the osteoclasts derived from the calvarial bone.
BPs are known to be very effective in inhibiting osteoclasts; however, it is not known if 
these drugs exert differential effects on osteoclasts that are derived from craniofacial skeletal 
tissues. Recent reports of ONJ developing in cancer patients treated with denosamab 
(Prolia™), an anti-RANK (receptor activator of nuclear factor-κB) ligand inhibitor,53,54 
suggest that the osteoclast derivation or the specific cell environment may influence the 
development of ONJ. Whether differences in the site-specific osteoclast response to BPs 
contribute to the pathophysiology and localization of ONJ is not known and bears further 
investigation.
Effect of BPs on bone vascularity and angiogenesis
Several authors have postulated that the initiating event in ONJ is a compromise in bone-
blood supply caused by exposure to BPs. As such, similarities have been drawn between 
ONJ and ORN, where patients develop necrotic bone as a consequence of decreased bone 
vascularity in the setting of radiation-induced fibrosis. In support of this theory, Kapitola et 
al.55 found that rats treated with pamidronate alone experienced an overall reduction in 
bone-blood flow and bone resorption rates (as measured by the uptake of 85Sr-
microspheres, density and ash weight of bone, and urinary excretion of the resorption 
markers pyridinoline and deoxypyridinoline) compared to controls being treated with 
growth hormone alone or growth hormone plus pamidronate. However, there appear to be 
distinct differences between ONJ and ORN, both clinically and microscopically. While 
ORN almost never occurs in the maxilla, the ratio of maxillary to mandibular lesions in ONJ 
is less dramatic (2:1),11 with a significant number of cases described in the maxillary bone. 
Anatomically, the overwhelming mandibular predilection of ORN—a condition 
characterized by hypovascularity, hypoxia, and hypocellularity56—makes sense as the 
mandible is supplied by one major vessel. Moreover, ONJ may also differ from ORN 
histologically. Hansen et al.20 found an increase in vessel hyalinization and decrease in 
cellularity in ORN specimens compared to ONJ specimens.
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The significant incidence of ONJ in the maxilla suggests that alteration in bone blood flow 
at the tissue level may not be solely responsible for induction of bone necrosis. A number of 
studies have shown that BPs may inhibit angiogenesis at the level of the endothelial cell. 
Wood et al.57 demonstrated in vitro that zoledronate inhibited proliferation of human 
endothelial cells stimulated with fetal calf serum, basic fibroblast growth factor, and 
vascular endothelial growth factor (VEGF). This group also found that endothelial cell 
adhesion, migration, and vessel sprouting were also significantly reduced by zoledronate. 
Bezzi et al.58 investigated the effects of zoledronate and clodronate on human umbilical vein 
endothelial cell (HUVEC) in vitro and confirmed that zoledronate but not clodronate 
inhibited integrin-mediated adhesion and migration. Furthermore, they found that 
zoledronate disrupted focal adhesions and actin stress fibers and enhanced tumor necrosis 
factor-induced cell death of HU-VECs that was independent of nuclear fragmentation or 
capase activity.58 Fournier et al.59 found that endothelial cells treated with a variety of BPs, 
including zoledronate, reduced proliferation, induced apoptosis, and decreased capillary-like 
tube formation in vitro. To investigate the effects of BPs in vivo, these authors examined 
revascularization in the prostate gland of rats induced by testosterone. They found a 50% 
reduction in revascularization in rats treated with zoledronate. In a mouse model of human 
cervical carcinoma (estrogen treated K14-HPV16 female transgenic mice or HPV/E2 mice), 
Giraudo et al.32 found that treatment with zoledronate inhibited angiogenesis around the 
tumor, as well as progression of premalignant lesions and tumor growth. The authors 
suggested that BPs may be efficacious as an adjunct to treatment for cervical carcinoma.32 
Hamma-Kourbali et al.60 used a non-nitrogen-containing BP (BP7033) to treat a human 
epidermoid carcinoma cell line and were able to inhibit Ras processing as well as decrease 
VEGF and matrix metalloproteinase-2 (MMP-2) in vitro. When these tumor cells were 
introduced into nude mice, the BP was able to inhibit tumor growth and angiogenesis. An in 
vitro study by Okamoto et al.61 showed that incadronate inhibited advanced glycation 
endproduct (AGE)-induced angiogenesis, a process that is accelerated in diabetics, 
suggesting that BPs may prove valuable in the inhibition of vascular endothelial 
proliferation in diabetic retinopathy. Finally, BPs have been shown in vitro to inhibit MMPs 
1, 2, 3, 7, 8, 9, 12, 13, and 14. MMPs are up-regulated in a number of inflammatory 
conditions and appear to play a role in tumor metastases.62
In human studies, Santini et al. have shown in several series that patients with advanced 
solid cancers and associated bone metastases exhibit significantly reduced serum VEGF 
when treated with zoledronate or pamidronate.63–65 Vincenzi et al.66 confirmed these 
findings and further observed that the reductions in VEGF levels were maintained 
throughout their study period, and that the greatest decrease was noted at 21 days. This 
group also found that cancer patients receiving a single infusion of zoledronate showed 
significant decreases in platelet-derived growth factor (PDGF) levels, although this 
reduction was only sustained for 2 days.64
A recent meta-analysis of three large clinical trials compared the incidence of ONJ in breast 
cancer patients receiving bevacizumab (avastin, anti-VEGF-1 monoclonal antibody) versus 
placebo and in patients with and without BP therapy. Although there were significant 
limitations to the study, the analysis failed to show an increased incidence in ONJ secondary 
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to bevacizumab therapy in patients with locally recurrent or metastatic breast cancer treated 
with chemotherapy, with or without BPs.67
Many questions remain as to whether the antiangiogenic properties of BPs play a major role 
in the pathogenesis of ONJ. The notable incidence of ONJ within the maxilla appears to 
refute BP-induced inhibition of angiogenesis as the sole cause of ONJ. Furthermore, the 
antiangiogenic theory fails to explain why bone necrosis associated with BPs is not 
commonly seen in bones other than the jaws. It is likely, therefore, that the antiangiogenic 
properties of BPs contribute to the development of ONJ but that other factors, including 
intrinsic anatomic and physiologic differences in the gnathic bones, may play roles as well.
ONJ, altered wound healing, and immune dysfunction
Diabetes
It is well known that patients with diabetes have impaired wound healing that often results in 
chronic skin ulcerations, nonunion of fractures, and severe periodontal disease.68,69 Wound 
healing is a complex, multistep process that results in the restoration of an intact epidermal 
barrier. Appropriate wound healing relies on three overlapping functions of keratinocytes 
and fibroblasts: migration, proliferation, and differentiation. Directed migration is critical to 
wound healing, and defects in this process are associated with the clinical phenotype of 
chronic nonhealing wounds. Endothelial cells, macrophages, and platelets as well as 
numerous growth factors, surface receptors, and extracellular matrix proteins are also critical 
in the wound healing process. While it seems plausible that the impaired wound healing seen 
in diabetic patients could play a role in the development of ONJ, evidence is limited to a 
single brief report from Khamaisi et al.70 This group evaluated the frequency of diabetes 
mellitus in 31 patients with ONJ compared with a control group of 33 oncological patients 
without ONJ. The diagnosis of diabetes mellitus was based on the presence of two 
consecutive fasting blood glucose levels greater than 7mmol/L. Impaired fasting glucose 
levels were defined as levels of 100 or greater and 7mmol/L or less. Of the 31 patients with 
ONJ, 58% were found to either have diabetes or impaired fasting glucose (including one 
patient with gestational diabetes). Twelve percent of patients in the control group had 
diabetes. Statistical analysis was significant between the two groups when all diabetic-
related diagnoses (diabetes, impaired fasting glucose, and gestational diabetes) were 
grouped together and compared to controls. Clearly, further investigations to define the role 
that impaired healing in diabetic patients plays in the development of ONJ are critical.
Chemotherapy and corticosteroids
Osteonecrosis (aseptic necrosis, avascular necrosis) of bones other than the craniofacial 
skeletal has been associated with sickle cell anemia, impairment of local bone circulation, 
Gaucher’s disease, and collagen vascular diseases. Although it is rare, several cases of 
osteonecrosis have been documented in patients receiving chemotherapy without 
concomitant corticosteroids.71–73 Interestingly, one of these cases was a patient with acute 
myelogenous leukemia who developed a large area of necrotic bone associated with several 
periodontally involved teeth. Chemotherapeutic agents have multiple effects on cells and are 
known to inhibit proliferation of oral mucosal cells often leading to mucositis and stomatitis. 
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It would therefore seem likely that many of these agents could potentially play a role in the 
initiation or perpetuation of an ONJ lesion. The paucity of large well-controlled prospective 
studies and the fact that most patients reported in ONJ case series are being treated for 
metastatic bone disease with BPs and concomitant chemotherapy makes it difficult to assess 
the exact role of chemotherapeutic agents in the pathophysiology of this condition.
The inhibition of wound healing by corticosteroids is a well-recognized side effect of these 
medications. In addition, osteonecrosis, secondary to both intravenous and oral 
corticosteroids, has been well documented, most often seen in patients treated for 
malignancies or rheumatic diseases. The most common site of steroid-induced osteonecrosis 
is the femoral head; however, involvement of the knees, wrists, humerus, patella, and 
scapula has also been described.73 Similar to ONJ, the etiology and natural history of 
steroid-induced osteonecrosis is not well understood; however, there is some evidence that 
suggests a genetic predisposition to this condition.74 Several retrospective, uncontrolled 
studies have noted a high percentage of patients with ONJ that are receiving 
corticosteroids.10,14,74–77
Recently several animal models for ONJ have been developed. Bi et al.78 were the first to 
report on a murine model that showed exposed bone in the jaws following a 3-week 
intraperitoneal administration of zoledronate and dexamethasone, tooth extraction, and an 
additional 3- to 12-week course of drugs. While ONJ-like lesions developed in the animals 
treated with zoledronate and dexamethasone, the addition of doxetaxel resulted in 
significantly larger areas of ONJ-like lesions in these mice. Clearly, this murine model, as 
well as other newly described animal models, will aid in defining the specific role that 
steroids and chemotherapy play in the pathogenesis of ONJ.
Gamma/delta T cells
Nitrogen-containing BPs are well-known to cause a flu-like acute phase reaction in about 
one third of patients, predominantly after a first intravenous administration.79 This acute 
phase reaction has been linked to the inhibition of the enzyme farnesyl pyrophosphate 
(FPP)-synthase by the N-containing BPs. As a result of this enzyme inhibition, isopentenyl 
pyrophosphate (IPP) accumulates intracellularly, and is presented to Vγ9Vδ2+ T cells by an 
as yet unidentified mechanism.79 The result is the activation and proliferation of γ, δ T 
cells,80–82 cytokine release, and flu-like symptoms.83,84 This mechanism is now also being 
explored for immunotherapy purposes to treat tumors, as N-containing BPs have been 
shown to increase intracellular IPP concentrations in tumor cells in vitro.79 Inflammatory 
cells have been shown in bone biopsies from ONJ patients, hence, ONJ may also be linked 
to gamma-delta T cell activation and proliferation. To our knowledge, however, there are no 
data available on a potential relationship between developing ONJ and flu-like symptoms 
induced by N-containing BPs. Although interesting, the involvement of gamma-delta T cells 
in ONJ presently remains a hypothesis.
Landesberg et al. Page 12
Ann N Y Acad Sci. Author manuscript; available in PMC 2015 June 23.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Other contributing factors
Hypercoagulable states
In the mid-1990s, a series of reports from one group of investigators surfaced implicating 
hypercoagulopathies with idiopathic osteonecrosis of the femoral head. Idiopathic 
osteonecrosis—as opposed to secondary osteonecrosis that occurs in the setting of 
predisposing factors like alcoholism, corticosteroid use, and systemic diseases—is 
characterized histologically by venous hypertension of the bone.85–88 This group theorized 
that patients suffering from a hypercoagulopathy—such as an increased tendency to develop 
thrombosis (thrombophilia) or a reduced ability to lyse thrombi (hypofibrinolysis)89—are 
predisposed to persistent thrombosis, which may lead to impaired venous drainage, 
increased medullary pressure, and subsequent anoxic bone necrosis.90–95 The existence of a 
hypercoagulable state can be assessed by a number of specialized serologic tests, including 
measurement of heritable thrombophilic Factor VIII levels, resistance to activated protein C 
(RAPC), protein C deficiency levels, anticardiolipin antibodies (ACLA) levels, tissue 
plasminogen activator activity (tPA-Fx), plasminogen activator inhibitor activity (PAI-Fx), 
and lipoprotein A levels (LP(a)). In one of their largest series,96 these authors evaluated 71 
patients with idiopathic osteonecrosis of the femoral head for coagulopathies. They found 
that 19/71 (27%) of patients with idiopathic osteonecrosis had serologic measure of 
thrombophilia compared to 3/66 (5%) of race- and sex-matched controls. Similarly, 25/69 
(36%) of the osteonecrosis patients had a serologic measure of hypofibrinolysis compared to 
12/67 (18%) of controls. Similar results were found in other studies by the same group of 
investigators.91,94,97 Of particular interest, these authors have recently suggested that such 
hypercoagulable states may contribute to the development of necrotic lesions of the jaws.98 
The role of hypercoagulopathies in the development of ONJ warrants further investigation.
Calcium and parathyroid hormone levels
It has been previously shown that patients taking BP can develop hypocalcemia and 
secondary hyperparathyroidism.99,100 The role of parathyroid hormone (PTH) in promoting 
cell proliferation and cancer progression is of interest in the oncologic population. One study 
showed that metastatic breast and prostate patients treated with zoledronate who 
demonstrated an elevation in PTH levels had an overall increased risk of mortality.89 
Similarly, PTH increase in metastatic prostate patients receiving zoledronate had an 
increased risk of disease progression.101 Intriguingly, it has been shown that BP-induced 
secondary hyperparathyroidism and consequent renal osteodystrophy may predispose to 
spontaneous osteonecrosis of the femoral head.102
In a short letter to the Annals of Oncology, Ardine et al.103 examined a small group of breast 
cancer patients who developed ONJ while being treated with zoledronate. The median time 
from initiation of therapy to ONJ development was 14 months. The control population 
consisted of breast cancer patients also receiving zoledronate but who did not develop ONJ 
over 18 months of treatment. All patients were assessed for corrected calcium and PTH 
levels at baseline and the following time points: each of the 4 months prior to ONJ onset in 
the ONJ group and between the 12th and 14th months of zoledronate treatment in the control 
group. These authors found that the ONJ patients exhibited lower calcium and higher PTH 
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values compared to controls at all evaluated time points and that the differences often 
achieved statistical significance. Interestingly, both patient populations exhibited an initial 
increase in PTH levels upon administration of the BP, although the increase was transient in 
the control group. These findings suggest that ONJ patients may be predisposed to persistent 
hypocalcemia and hyperparathyroidism compared to patients who do not develop ONJ, 
suggesting a role for calcium and PTH in ONJ. It is difficult to draw definitive conclusions 
from this study given the small size of the ONJ subset and that little information was 
provided regarding the control population. However, it appears that this is a potential avenue 
of future investigations in the study of ONJ pathogenesis.
From the bench to the bedside: which patients are at risk of ONJ?
A number of mechanisms have been described above that are likely involved in the 
pathophysiology of ONJ. In addition, we have outlined some important clinical risk factors 
that have been implicated in the development of ONJ lesions. The challenge for the clinician 
is to stratify risk for the development of ONJ in the clinical setting. Recently, a new clinical 
scale, the UCONNS (University of Connecticut OsteoNecrosis Numerical Scale), an 
instrument that weighs the various risk factors described herein, has been developed in order 
to address this issue (Appendix A). Future validation of this scale in our patient populations 
will be carried out with the goal that clinicians will be able to appropriately monitor and 
prevent ONJ.
Conclusion
The pathophysiology of ONJ is not well defined and likely is multifactorial in nature. While 
this condition is most likely associated with BP use, a causal effect has yet to be 
demonstrated. The unique anatomy, biomechanical forces, and microbial environment of the 
oral cavity may explain why ONJ lesions show preference for the craniofacial region. 
Furthermore, it appears likely that immunosuppression and altered wound healing play a 
role in the development of ONJ. We have presented data supporting the theory that ONJ 
lesions are initiated by trauma to the oral mucosa and BPs sequestered in the jaw bones 
inhibit wound closure—an “outside-in theory.” It is evident that much work remains before 
the pathophysiology of ONJ is definitively elucidated.
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Appendix
The University of Connecticut OsteoNecrosis Numerical Scale (UCONNS): A Proposed 
Predictive Index for ONJ Risk Assessment
Regina Landesberg,1 Pam Taxel,2 Susan Tannebaum,3 David Shafer,4 David Pendrys,5 and 
Khalid Almas6
1Associate Professor, Division of Oral and Maxillofacial Surgery, School of Dental 
Medicine. 2Associate Professor, Department of Medicine, Division of Endocrinology and 
Metabolism, School of Medicine. 3Associate Professor, Department of Medicine, Division 
of Oncology, School of Medicine. 4Associate Professor, Division of Oral and Maxillofacial 
Surgery, School of Dental Medicine. 5Associate Professor, Division of Behavioral Sciences 
and Community Health, School of Dental Medicine. 6Assistant Professor, Division of 
Periodontology, School of Dental Medicine, University of Connecticut Health Center, 
Farmington, Connecticut
Osteonecrosis of the jaws (ONJ) was first reported in 2003 and, despite numerous case 
reports and a limited number of retrospective and prospective clinical studies, the 
pathophysiology, comorbidities, and potential risk factors for the development of the 
condition remain ill-defined. While ONJ appears to be associated with the use of nitrogen-
containing BPs, numerous other factors potentially contribute to the occurrence of this 
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disease. Furthermore, while a number of medical and dental societies have put forth clinical 
definitions and recommendations for prevention and treatment, determination of the 
importance of specific risk factors is often hampered by incomplete or nonspecific patient 
data. Consequently, we have developed an instrument, the University of Connecticut 
OsteoNecrosis Numerical Scale (UCONNS), to assess some of the suspected risk factors for 
the development of ONJ (Appendix Table A1). It appears that in order for our knowledge of 
ONJ and its associated risks to move forward, there needs to be a standardized reporting 
system and assessment of patients between institutions. The great majority of suspected risk 
factors for ONJ have not been scientifically validated; thus, the values assigned within are 
based on our best assessment of the presently available literature. The scale is meant to be a 
starting point and will require modification as more data becomes available. We plan to test 
the validity of this instrument by applying it to our patient population data in both 
prospective and retrospective analyses.
Appendix Table A1
University of Connecticut OsteoNecrosis Numerical Scale
1 Bisphosphonate Use (Maximum 15)
Oral
Points Criteria
1 Initiation of therapy - <3 Years
2 3 – 5 Years
3 > 5 Years
Reclast (IV Once a Year)
Points Criteria
1 < 3 Doses 5 – 10 mg
2 3 – 5 Doses 15 – 20 mg
3 6 or greater Doses 25 mg or greater
Zoledronate (Zometa)
Points Criteria
3 1–6 Doses 4 –24 mg
4 7–12 Doses 28 – 48 mg
5 13–18 Doses 52 –72 mg
6 19 – 24 Doses 76 –96 mg
7 25–36 Doses 100 – 144 mg
8 > 36 Doses > 144 mg
Pamidronate (Aredia)
Points Criteria
2 1 – 12 Doses
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3 13 – 24 Doses
4 > 25 Doses
2 Proposed Oral/Maxillofacial/Dental/Surgical Procedures (Maximum 5)
Points Criteria
0 Prophylaxis
0 Restorative procedure to tooth structure (Amalgam, crown & bridge)
1 Nonsurgical endodontic treatment
1 Denture Fabrication/New Denture insertion (prior 12 months)
2 Scaling and Root Planning, soft tissue surgery, non-immediate implant placement (prior 12 months)
3 Periodontal osseous surgery, surgical endodontic procedure, immediate implant placement (prior 12 
months)
4 Routine extraction (prior 12 months)
5 Surgical extraction, surgical endodontic procedure, bone augmentation (prior 12 months)
6 Surgical resection of mandible/maxilla (prior 12 months)
3 Oral Health (Maximum 7)
Points Criteria
0 Good Oral Hygiene, minimal or no plaque (zone 1) no tooth mobility, no spontaneous bleeding, no 
visible inflammation
1 Fair Oral Hygiene, visible plaque (zone 2), 1+ tooth mobility visible inflammation, papillary 
inflammation
2 Poor oral hygiene, visible plaque (zone 3), 2+ tooth mobility, spontaneous bleeding, 3+ inflammation
4 Active infection/suppuration
5 Osteomyelitis
4 Medical Condition (Maximum 10)
Points Criteria
0 Health
1 HIV
2 Diabetes, Rheumatic Disorders
2 Soft tissue cancers other than breast/prostate
3 Breast, Prostate Cancer
5 Multiple myeloma
5 Comorbidities (Maximum 10)
Points Criteria
0 Nonsmoker
1 Prior smoker, Quit > 6 mos ago
Inhaled steroids (within 12 months)
2 Smoker, current or last month, >10 cigs/day
Steroids PO (within 12 months)
3 Steroids IV, IM (within 12 months)
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5 Immunosuppression, Chemotherapy, immune modulators (for rheumatic disorders, transplant patients), 
(within 12 months)
Risk Assessment
< 10 Minimal Risk
10 to 15 Moderate Risk
16 or above Significant Risk
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Figure 1. 
Cellular proliferation of oral keratinocytes with pamidronate. Low concentrations of 
pamidronate (0.003–0.03 mM) did not affect cell proliferation over the course of seven days. 
A higher dose (0.1 mM) significantly inhibited proliferation. *P < 0.05 when compared to 
controls.
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Figure 2. 
Caspase-3 activity in oral keratinocytes incubated with pamidronate. Pamidronate did not 
significantly increase caspase-3 activity in cells over a 48-h period when compared with 
controls. The positive control (+) was obtained by incubating cells with staurosporine and 
cycloheximide. * Significant increase compared with controls, P <0.05.
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Figure 3. 
Wound healing in oral keratinocytes with pamidronate. Cells were observed for 96 h after 
wounding in cell culture plates. Control wells exhibited significant migration into the 
wounded area from time of injury (A) to 96 h (B). Cells preincubated for 72 hours with 0.1 
mM pamidronate prior to wounding had greatly reduced migration from 0 (C) to 96 h (D). 
Data shown are representative of three independent experiments.
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Figure 4. 
Cellular proliferation of human oral keratinocytes with pamidronate. Low concentrations of 
pamidronate (0.003–0.03 mM) did not affect cell proliferation over the course of seven days. 
A higher dose (0.06 mM and 0.1 mM) significantly inhibited proliferation. *P <0.05 when 
compared to controls.
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Figure 5. 
Difference in cellular proliferation of human alveolar and long bone. Proliferation of long 
bone cells in culture was significantly less over the course of seven days compared with 
alveolar bone cells.
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